6th Diabetes Drug Discovery & Development
29 Apr 2013 - 30 Apr 2013 - Boston, MA, USA
The International Diabetes Federation estimates that more than 285 million people world-wide have diabetes and 438 million people will have this disease within 20 years. Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of all diabetes and is characterized by insulin resistance combined with relatively reduced insulin secretion. The seven major markets for diabetes are expected to grow to 35 billion in 10 years driven by patient population expansion and novel therapies.
Come and join other diabetes experts at GTC’s 5th Diabetes Drug Discovery and Development Conference and hear key thought-leader`s opinions to these questions and many more. This important meeting will be held on April 19-20, 2012 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current and clinical drug development.
Regulatory Guidance and Updates (joint session)
New Therapeutic Targets for Diabetes
Clinical Drug Development in Diabetes
Diabetes and the Metabolic Syndrome Drug Development
Beta Cell Regenerative Therapy for Diabetes
Panel Discussion: Diabetic Devices & Technology
Panel Discussion: Beyond HbA1c - Are there Better Endpoints for Clinical Trials?
This conference is also part of the 2nd Diabetes Summit which consists of one other conference: 2nd Diabetes Partnering & Deal Making